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Abstract
Background: Evidence has accumulated that multiple genetic and environmental factors play important roles in
determining susceptibility to type 2 diabetes (T2D). Although variants from candidate genes have become prime targets for
genetic analysis, few studies have considered their interplay. Our goal was to evaluate interactions among SNPs within
genes frequently identified as associated with T2D.
Methods/Principal Findings: Logistic regression was used to study interactions among 4 SNPs, one each from
HNF4A[rs1884613], TCF7L2[rs12255372], WFS1[rs10010131], and KCNJ11[rs5219] in a case-control Ashkenazi sample of 974
diabetic subjects and 896 controls. Nonparametric multifactor dimensionality reduction (MDR) and generalized MDR
(GMDR) were used to confirm findings from the logistic regression analysis. HNF4A and WFS1 SNPs were associated with
T2D in logistic regression analyses [P,0.0001, P,0.0002, respectively]. Interaction between these SNPs were also strong
using parametric or nonparametric methods: the unadjusted odds of being affected with T2D was 3 times greater in
subjects with the HNF4A and WFS1 risk alleles than those without either (95% CI = [1.7–5.3]; P#0.0001). Although the
univariate association between the TCF7L2 SNP and T2D was relatively modest [P = 0.02], when paired with the HNF4A SNP,
the OR for subjects with risk alleles in both SNPs was 2.4 [95% CI = 1.7–3.4; P#0.0001]. The KCNJ11 variant reached
significance only when paired with either the HNF4A or WFSI SNPs: unadjusted ORs were 2.0 [95% CI = 1.4–2.8; P#0.0001]
and 2.3 [95% CI = 1.2-4.4; P#0.0001], respectively. MDR and GMDR results were consistent with the parametric findings.
Conclusions: These results provide evidence of strong independent associations between T2D and SNPs in HNF4A and
WFS1 and their interaction in our Ashkenazi sample. We also observed an interaction in the nonparametric analysis between
the HNF4A and KCNJ11 SNPs (P#0.001), demonstrating that an independently non-significant variant may interact with
another variant resulting in an increased disease risk.
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Introduction
Type 2 diabetes (T2D) has become one of the leading and
fastest growing health problems in the world affecting approxi-
mately 18 million Americans and over 170 million individuals
worldwide in 2000. By 2030 these estimates are expected to rise to
over 30 million in the United States and 366 million worldwide
[www.who.int/diabetes/facts/world_figures]. Although its exact
etiology is unknown, accumulating evidence recognizes T2D as a
quintessential multifactorial disease, resulting from numerous inter-
actions between multiple genetic variants, along with environmental
factors related to diet, exercise, stress, and medical treatment [1].
Given its position as one of the leading health problems in the world,
in the last few years T2D has been the target of 15 genome wide
association studies (GWAS) [2] and multiple candidate gene studies
(reviewed in [3] and [4]). These studies have been successful in
identifying individual variants in a variety of genes that may play
a role in the etiology of T2D. However, because of practical
and statistical challenges, none of the GWAS have considered
interactions among the thousands of GWA variants, and only
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relatively few candidate gene studies have pursued such studies
[5–13]. These studies generally include only those variants in their
interaction analyses that have shown some nominal probability of
marginal significance (e.g. p,0.05) in previous studies. However,
there are genetic models in which variants show no independent
association with the trait of interest, but which, in concert with other
variants, do provide evidence of interaction effects [14]. This
phenomenon has also been studied and documented in animal
models [15,16].
In the present study we investigated the importance of gene-
gene interplay on type 2 diabetes in a case-control sample of
Ashkenazi subjects. Four genes, TCF7L2, HNF4A, KCNJ11, and
WFS1, all with strong prior evidence for association with T2D and
with credible biological mechanistic effects on T2D, were chosen
for analysis. One Single Nucleotide Polymorphism (SNP) was
selected for genotyping from each of these four candidate genes
based on previous studies in which the SNP was shown to be
directly associated with T2D or in high linkage disequilibrium with
a SNP identified as associated with T2D. SNPs in the TCF7L2
gene were selected as being the only truly universally T2D positive
SNPs that had been identified at the start of this study. Two
intronic SNPs in high LD (r2 = 0.77) in the TCF7L2 gene,
rs12255372 and rs7903146, had been identified as being
associated with T2D in at least 49 articles. We chose to genotype
rs12255372 in our Ashkenazi population. HNF4A is a transcrip-
tion factor regulating a network of genes controlling insulin
secretion and glucose regulation. Recently we have found the
HNF4A SNP, rs1884613, to be strongly associated with T2D in an
Ashkenazi case-control sample unrelated to the sample in our
current study [17]. Rs1884613 is located upstream of HNF4A and
has no known function. The potassium channel gene, KCNJ11 on
chromosome 11p15.1, regulates glucose-induced insulin secretion
in pancreatic beta cells [18–20]. With the exception of Ashkenazi
samples, coding SNP rs5219 (E23K) in KCNJ11 has been
consistently associated with T2D populations over many years
[21]. We included this SNP in our analysis to determine if its effect
might be amplified by interactions with other genes in the
Ashkenazi population. Although mutations in the WFS1 gene
have long been known to be causal in autosomal recessive
Wolfram syndrome [22], recently several studies have implicated
WFS1 SNPs also to be associated with T2D [23–26]. Four of the
five PubMed citations for T2D studies using rs10010131 found
evidence for an association with T2D, including a meta analysis of
previous studies from Sweden, Finland, and France, which
reported a highly significant finding for this SNP [23]. In addi-
tion, rs10010131 was one of 2 intronic WFS1 SNPs in strong
disequilibrium (r2 = 0.98) found to be significant in a study of T2D
in UK and Ashkenazi populations studying genes involved in
pancreatic b cell function [25] in both populations. Our multilocus
analysis strategy makes use of the traditional parametric approach
of logistic regression and the nonparametric method of multifactor
dimensionality reduction (MDR) [27].
Methods
Ethics Statement
This study was approved by the local ethics committee of each
center where samples were collected: the committee on Research
Involving Human Subjects of The Hebrew University-Hadassah
Medical School, Jerusalem, Israel; Committee on Clinical
Investigations at Albert Einstein College of Medicine; the Human
Research Protection Office at Washington University in St. Louis.
Written informed consent was obtained from all participants
before participation in the study.
Samples
To minimize potential genetic heterogeneity, 1,870 subjects
(974 cases, 896 controls) were recruited for a cross-sectional study
from the Ashkenazi Jewish population. Blood was drawn from all
subjects, and age of diagnosis was determined for cases by
questionnaire and review of medical history. Subjects had been
determined to have T2D if their fasting glucose was greater than
140 mg/dl on more than 1 occasion or random glucose was
greater than 200 mg/dl on at least two occasions [28]. Ashkenazi
Jews are a relatively homogeneous population thought to have
developed from a founder population approximately 500 years ago
[29]. Subjects who self identified as Ashkenazi were accepted into
the study only if all four grandparents also self identified as
Ashkenazi and were born in Northern or Eastern Europe. Most of
the subjects in this study reside in Israel (N= 1,600); the remainder
are United States citizens residing in New York City, ascertained
from the Einstein Longevity Study [30,31]. The NYC portion of
our sample contained, with one exception, only controls. Sex,
body mass index (BMI) and current smoking status were available
for possible inclusion in the analyses.
DNA samples for the Israeli Ashkenazi subjects were obtained
from Dr. Benjamin Glaser and genotyping data from the NYC
sample were obtained from Dr. Gil Atzmon. Genotypes for Israeli
Ashkenazim SNPs were assessed by PCR amplification of genomic
DNA and Pyrosequencing technology (Biotage AB, Uppsala,
Sweden) as previously described [32]. Genotypes for the NYC
sample were assessed by Pyrosequencing technology (Biotage AB,
Uppsala, Sweden) as discussed in [33].
Data Analyses
Exact Hardy Weinberg Equilibrium (HWE) tests were per-
formed for each SNP independently among cases and controls.
Logistic regression models (SAS V9.1.3) were used to assess the
effects of each of the 4 SNPs on T2D with and without adjusting
for sex and body mass index (BMI). Smoking status was available
for over 98% of controls, but only 25% of cases and therefore was
not included in the data analyses. An additive model was used to
code SNPs for the ‘risk’ allele, the allele that increased the
probability of being a case. Accordingly, ‘0’ indicated the subject
was homozygous for the non-risk allele; the heterozygote was
coded ‘1’, and those who were homozygous for the risk allele were
coded ‘2’. Interaction effects between SNPs were modeled using
four mutually exclusive levels: (1) subjects without either risk allele,
(2) subjects with one risk allele in the first SNP but without the risk
allele in the second SNP, (3) subjects without the risk allele in the
first SNP but with the risk allele in the second SNP, and (4)
subjects with both risk alleles. Level (1), was considered the
reference group [34,35].
Multifactor dimensionality reduction (MDR, V2.0 Beta 2) was
used to verify our interaction results. MDR was initially
introduced by Ritchie et al., 2001, [36] as a genetically model-
free and non-parametric alternative to logistic regression [27,37].
A benefit of these non-parametric models is minimizing statistical
issues that frequently arise when using traditional parametric
models such as logistic regression. In particular, the possibility
often exists that few or no observations will be assigned to
contingency table cells when testing for interactions, thereby
invalidating the resulting parameter estimates. Briefly, MDR acts
by reducing a set of multilocus genotypes to one dimension with
two groups: a high-risk and a low-risk set of genotypes. A
particular multilocus genotype can be declared to be high-risk if
the ratio of number of cases to controls exceeds the proportion of
cases in the total sample. By grouping the high-risk multilocus
genotypes together and the low-risk genotypes together, the model
SNP Epistasis & Ashkenazim T2D
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is reduced to one dimension, that is, essentially 1 variable with 2
possible values: high or low risk 2-locus genotypes. Models are
evaluated on the testing balanced accuracy statistic (TBA) [38], the
cross-validation consistency (CVC) [39], and the statistical signif-
icance of the model. The TBA measures how often individuals are
correctly classified with respect to their case/control status, and the
cross-validation consistency (CVC) evaluates the consistency with
which individuals are classified. Heuristically, a satisfactory TBA
score is above 0.55 (http://compgen.blogspot.com/2006/12/mdr-
101-part-4-results.html). We used 10,000 permutations to deter-
mine the statistical significance of the best models. These data were
also analyzed using an extension of the MDR algorithm that
includes adjustment for covariates, the Generalized Multifactor
Dimensionality Reduction (GMDR, V0.7) software package [40].
Results
All SNPs were in Hardy-Weinberg equilibrium [P.0.23].
Characteristics of the cases and controls are displayed in Table 1.
As expected, BMI was significantly greater among cases than
controls [29.5 vs. 25.9, P#0.0001]. Although there were
significantly more males among cases than controls [49% vs.
42%, P= 0.002], the proportion among the controls recruited in
Israel versus the U.S. did not differ [P = 0.82]. The age variable
was highly correlated with the diagnosis of T2D; the mean age of
examination for controls was 72 (69.3) years versus 47 (67.8)
years for diagnosis of cases (p,0.0001). Accordingly, this variable
was not included in the statistical analyses. The average age of
cases when ascertained for this study was 64 years. Means and
standard deviations for cases’ HbA1c measurements and fasting
glucose for controls are displayed in Table 1. HbA1c measures on
controls were not recorded since at the time of ascertainment it
was not an accepted diagnostic tool. Since glucose is totally
controlled by treatment and can vary considerably from day to
day, fasting glucose was not measured in the cases.
As seen in Table 2, the genotype frequencies between cases
and controls were significantly different for the HNF4A and
WFS1 genotypes [P,0.0001, ,0.0008, respectively]. We note that
Ashkenazi cases had a greater excess of heterozygous and homo-
zygous HNF4A genotypes with the risk allele than expected by
chance, indicating a dominant mode of inheritance. Conversely,
WFS1 case/control genotypes indicate a recessive mode of inheri-
tance. Diverging from the results of multiple recent studies in non-
Ashkenazi populations [41], the TCF7L2 genotype frequencies
between cases and controls only minimally differed (P=0.055), and
the KCNJ11 genotypes showed no difference with the diagnostic
status of the Ashkenazi subjects [P,0.55]. The OR and P-values of
the logistic regression analyses on the additive genetic models for
each SNP, with and without covariates, are displayed in Table 3. Of
the four SNPs genotyped, only the HNF4A and WFS1 SNPs were
significant with or without covariates after a Bonferroni correction
for multiple tests; the P-value for rs12255372 in TCF7L2 was 0.02.
Table 4 presents the results of models for the interaction effects of
the genotypes. The risk of a diagnosis for T2D is greatest in subjects
with the HNF4A and WFS1 SNP risk alleles versus those with
neither risk allele [OR=3.0, 95% CI=1.7–5.3]. There is no or







Category Mean 6 STD Mean 6 STD P-value
Age(1) 47.167.8 72.369.3 ,0.0001
BMI 29.465.0 25.86 4.2 ,0.0001
Sex (% male) 49.5 42.2 0.0018
Smoking (% Current) 11.6 10.4 0.61
Fasting Glucose (mmol/L)(2) NA 92.5637.3
HbA1c(2) 7.961.5 NA
Site (% Israeli) 100.0 69.9 ,0.0001
(1)Age at diagnosis for cases; age at examination for controls.
(2)Fasting Glucose was measured only in controls; HbA1c was measured only in
cases.
doi:10.1371/journal.pone.0009903.t001
Table 2. Case and Control Genotype Frequencies.
Gene (rs number) Genotype Cases (%) Controls (%)
HNF4A (20q12-q13.1) CC 276(52.5) 473(66.1)
(rs1884613) CG 200(38.0) 215(30.1)
GG 50(9.5) 27(3.8)
Total 526(42.4) 715(57.6)
X2 2df (P value) 31.2 (,0.0001)
MAF 0.23
KCNJ11 (11p15.1) AA 79(13.8) 100(11.7)
(rs 5219) AG 266(46.4) 404(47.9)
GG 228(39.8) 339(40.2)
Total 573(40.5) 843(59.5)
X2 2df (P value) 1.18 (0.55)
MAF 0.36
TCF7L2 (10q25.3) GG 217(37.7) 332(44.2)
(rs12255372) GT 281(48.8) 334(44.4)
TT 78(13.5) 86(11.4)
Total 576(43.4) 752(56.6)
X2 2df (P value) 5.82(0.055)
MAF 0.35
WFS1 (4p16,1) CC 441(52.3) 318(44.6)
(rs10010131) CT 343(40.7) 313(43.9)
TT 59(7.0) 82(11.5)
Total 843(54.2) 713(45.8)
X2 2df (P value) 14.30 (0.0008)
MAF(1) 0.30
(1)The ‘risk’ allele for the WFS1 SNP is the major allele, C. The risk allele for all
other SNPs is the minor allele.
doi:10.1371/journal.pone.0009903.t002
Table 3. Associations between SNPs in candidate genes and
T2D in the Ashkenazi population.
OR[95% CI](1) P-value OR[95% CI](2) P-value
HNF4A (rs1884613) 1.69[1.40–2.03] ,0.0001 1.77[1.39–2.24] ,0.0001
KCNJ11 (rs5219) 1.05[0.90–1.23] 0.52 1.02[0.83–1.26] 0.83
TCF7L2 (rs12255372) 1.21[1.03–1.42] 0.02 1.21[0.98–1.49] 0.07
WFS1 (rs10010131) 1.34[1.15–1.56] ,0.0002 1.30[1.06–1.58] 0.01
(1)Unadjusted.
(2)Adjusted by sex, BMI.
doi:10.1371/journal.pone.0009903.t003
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minimal increased risk for type 2 diabetes at these two loci if only
one risk allele is present: OR=1.8 [95% CI=1.1–3.2] for the
presence of the WFS1 risk allele but not the HNF4A risk allele, and
OR=1.8 [95% CI=0.8–4.1] for the presence of the HNF4A risk
allele but not the WFS1 risk allele. As noted in Table 3, the odds of
T2D for subjects with the TCF7L2 risk allele was 1.2 times greater
than subjects without the risk allele in the single SNP logistic
regression model. However, when coupled with either the HNF4 or
WFS1 genotype containing at least one risk allele, the unadjusted
odds of being affected increased, respectively, to 2.4 and 2.9 times
greater for subjects with the TCF7L2 risk allele than those with
neither risk allele. There was no evidence for an increased risk for
T2D due to the presence of the rs5219 [KCNJ11] risk allele
interacting with any other risk alleles, with or without covariates.
Results from the multilocus MDR and GMDR analyses are
summarized in Table 5. The CVCs indicate consistency in the cross
validation measures (10/10) across all models. Based on the testing
balanced accuracy (TBA) statistic and permutation p-values, the
most significant interactions, adjusted and unadjusted for covariates,
were pairs containing the HNF4A SNP: HNF4A x KCNJ11
(P= 0.001), HNF4A x TCF7L2 (P= 0.03), and HNF4A x WFS1
(P= 0.009). Adding covariates strengthened the results for HNF4A
x TCF7L2 (P,0.002) and HNF4A x WFS1 (P,0.004) interactions.
TCF7L2 x WFS1 (P= 0.01) was also significant, but not with the
inclusion of covariates. Over all, the parametric and nonparametric
results were consistent for the significant interactions between
HNF4A x KCNJ11, HNF4A x TCF7L2, and HNF4A x WFS1.
Consistency between the logistic regression and MDRmethods was
also observed in the KCNJ11 x TCF7L2 analyses in which neither
method indicated a significant interaction between the SNPs in
these genes. The KCNJ11 x WFS1 interaction was not significant in
the MDR analyses nor in the logistic regression if no WFS1 risk
allele was present. Higher order three way unadjusted MDR
interactions were nominally significant only if the HNF4A SNP was
one of the interacting SNPs. Among the three-way unadjusted
interactions, HNF4A xKCNJ11 x TCF7L2 was the most significant
interaction: P#0.001 (Table 5). To compare the parametric and
non-parametric methods, we analyzed the same three SNPs using
logistic regression, albeit, in contrast to an MDR or GMDR
analysis, contingency table cells that contain few or no observations
would result in unstable results, a situation that may occur when
interactions are introduced into the model [42]. A significant
association with T2D was found: OR=2.4, CI= [1.5–4.0],
P#0.0006. We also note that the MDR interaction between all
four SNPs was not significant without inclusion of sex and BMI. But
that increase was extremely modest (P= 0.03).
Discussion
Ourmain finding is that genetic interactions modulate the risk for
T2D in the Ashkenazi case-control sample. Specifically, the strength
of the association between polymorphisms of the HNF4A and
WFS1 genes and T2D in the parametric analyses indicated a three
fold increased risk of T2D for individuals who carry the risk alleles of
these polymorphisms compared to individuals whose genotypes
contain neither risk allele. This interaction was also echoed in the
MDR/GMDR analysis. Although the TCF7L2 SNP was not
strongly associated with T2D in this population, when TCF7L2 was
jointly analyzed with either of the HNF4A or WFS1 SNPs, more
than a two-fold increase in T2D risk was observed for subjects with
both risk alleles. This was also borne out in the nonparametric
MDR/GMDR analyses. While this phenomena has been discussed
in a theoretical context [14] and has been shown to exist in animal
models [15,16], it has not commonly been seen in human studies,
particularly one with thousands of variants, such as a GWA study in
which any SNPs that are not highly significant are often not
included in follow-up interaction or non-interaction studies. In this
analysis there was no evidence that the KCNJ11 SNP, rs5219,
altered the strength of the association in the parametric analysis
when paired with any other candidate SNP. The apparent
importance of rs5219 in the nonparametric interaction analysis
may have been the result of the presence of rs1884613 [HNF4A] in
the interaction models. However, it is difficult to understand the
disparity in the significance between the nonparametric HNF4A x
KCNJ11 x TCF7L2 interaction (P#0.001), and the HNF4A x
TCF7L2 x WFS1 interaction (P#0.01) given the significance of the
WFS1 versus the KCNJ11 SNPs in the logistic regression analyses.
To the best of our knowledge, this is the first time a significant
genetic interaction effect associated with T2D was reported in a
sample of Ashkenazi Jewish descent.
Among those who have reported on studies involving variants in
genes of interest in the current study is Weeden et al., 2006 [13]
who examined the relationship among rs5219 in the KCNJ11
gene, rs7903146 in TCF7L2, a SNP in high LD with rs12255372
(r2 = 0.75), and Pro12 in the PPARG gene in a sample of over
Table 4. Odds ratios and 95% Confidence Intervals (CIs) for
the Joint Effects of Candidate SNP Genotypes on Type 2
Diabetes.
Risk Risk Ashkenazi Sample
Gene Pair Allele 1(1) Allele 2(1) OR(95% CI)(2) OR(95% CI)(3)
HNF4A, KCNJ11 2 2 1.00 1.00
(rs1884613, 2 + 1.21(0.88–1.66) 1.06(0.73–1.55)
rs 5219) + 2 1.95(1.34–2.83) 2.25(1.40–3.62)
+ + 1.96(1.39–2.77) 1.82(1.19–2.76)
HNF4A, TCF7L2 2 2 1.00 1.00
(rs1884613, 2 + 1.43(1.05–1.96) 1.33(0.91–1.94)
rs12255372) + 2 1.88(1.29–2.74) 1.89(1.19–3.01)
+ + 2.43(1.72–3.42) 2.47(1.61–3.78)
HNF4A, WFS1 2 2 1.00 1.00
(rs1884613, 2 + 1.82(1.05–3.17) 1.86(0.99–3.49)
rs10010131) + 2 1.80(0.78–4.11) 2.46(0.91–6.63)
+ + 2.99(1.70–5.27) 3.27(1.71–6.26)
KCNJ11,TCF7L2 2 2 1.00 1.00
(rs 5219, 2 + 1.24(0.87–1.76) 1.16(0.73–1.82)
rs12255372) + 2 1.03(0.72–1.46) 0.89(0.57–1.39)
+ + 1.34(0.97–1.85) 1.17(0.77–1.78)
KCNJ11,WFS1 2 2 1.00 1.00
(rs 5219, 2 + 2.32(1.21–4.46) 2.70(1.30–5.60)
rs10010131) + 2 1.71(0.74–3.98) 2.04(0.78–5.31)
+ + 2.32(1.22–4.41) 2.17(1.07–4.44)
TCF7L2,WFS1 2 2 1.00 1.00
(rs12255372, 2 + 2.18(0.97–4.90) 2.18(0.87–5.45)
rs10010131) + 2 1.60(0.62–4.09) 1.68(0.58–4.85)
+ + 2.87(1.28–6.40) 2.69(1.09–6.66)
(1)Risk alleles 1 and 2 refer to the leftmost and rightmost genes in the ‘Gene
Pair’column. ‘2’ indicates absence of the risk allele; ‘+’ indicates presence of
the risk allele; allele1 and allele2 = ‘2’ is the reference group.
(2)Unadjusted.
(3)Adjusted for Sex, BMI.
doi:10.1371/journal.pone.0009903.t004
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6,000 subjects from the UK. Although no gene-gene interactions
were found, a strong positive relationship between the numbers of
risk alleles within a subject and risk of T2D was reported: subjects
with all six risk alleles had an OR of 5.7 [95% CI= 1.2–28.3] for
T2D compared to subjects with no risk alleles. Cauchi et al., 2008
[6] chose 22 SNPs in 14 loci from a previous GWA study to
replicate in four independent European samples, including an
Israeli Ashkenazi and Moroccan sample. However, they only
analyzed interaction effects in the French subset of their sample,
and none of their loci overlapped with any of those analyze in the
current study. Using MDR, Qi et al. [9] reported an interaction
between rs5219 in KCNJ11 and rs2144908 in HNF4A in a case-
control study of T2D in a sample of female subjects from the
Nurses’ Health Study. We note that rs2144908 is in complete LD
with rs1884613, r2 = 1. Therefore, our MDR finding of an
interaction between rs5219 and rs1884613 in the Ashkenazi
sample is a replication of the Qi et al. study. To the best of our
knowledge, Qui et al. was the first to report an interaction between
SNPs in the HNF4A and KCNJ11 genes.
A strength of the current study is that all subjects with T2D
were Ashkenazi Jews living in Israel. Almost 70% of the controls
were also ascertained in Israel, with the remainder Ashkenazi Jews
from the U.S. No differences were detected between the two
groups of controls regarding smoking status, BMI, or gender. By
choosing Ashkenazi Jews for both cases and controls, we have
minimized the potential of genetic heterogeneity. An additional
strength of this study is that the mean age at ascertainment of non-
T2D status in the control population was 76 years, whereas the
mean age of T2D diagnosis in the cases was 25 years less, adding
to the confidence that this control group is not at high risk for a
future diagnosis. Furthermore, the average age at diagnosis of the
cases was 47 years, relatively young, and therefore more likely to
be genetically predisposed to T2D [43].
A major challenge for studies such as ours and those that
investigate the interaction between thousands of variants is to
decipher the complexity of the genetic networks between the loci that
appear to have a statistical relationship [44]. In this study, we know
that WFS1 appears to be part of the mechanisms related to beta-cell
survival [45], and HNF4a may have proliferative and/or functional
effects. The functional effects may interact with survival–increased
function resulting in increased endoplasmic reticulum (ER) and/or
oxidative stress resulting in increased apoptosis. Inactivating
mutations in HNF4a have been shown to cause hyperinsulinemic
hypoglycemia during the fetal and newborn period, as well as
MODY diabetes in adolescence [46]. We still know very little about
whether T2D associated variants effects increased or decreased
expression of HNF4A. The mechanism for such effect is still not well
understood. Therefore it would be pure speculation to try to explain
the interactions found in this study on the basis of known function.
In conclusion, all four chromosomal regions investigated in this
study harbor T2D genetic variants that have been replicated in
published studies, but very few studies have considered their
interactions. Nevertheless, we fully expect that additional variants,
some rare, will be added to the growing list of polymorphisms that
influence T2D, and that the analyses of interacting variants will lead
to a better understanding of the biological pathways underlying
T2D. This knowledge will bring us closer to the development of
effective prevention and treatment strategies.
Table 5. Gene x Gene Interaction Models: MDR (without covariates) and GMDR (with covariates).
Interacting SNPs Covariates Number of Subjects CVC(1) TBA(2) 10,000 Permutations P-value
HNF4A x KCNJ11 none 1162 10/10 0.560 0.001
Sex,BMI 853 10/10 0.564 0.002
HNF4A x TCF7L2 none 1153 10/10 0.540 0.028
Sex,BMI 848 10/10 0.565 0.002
HNF4A x WFS1 none 1176 10/10 0.546 0.009
Sex,BMI 829 10/10 0.559 0.004
KCNJ11 x TCF7L2 none 1288 10/10 0.504 0.437
Sex,BMI 918 10/10 0.495 0.595
KCNJ11 x WFS1 none 1117 10/10 0.516 0.252
Sex,BMI 813 10/10 0.528 0.146
TCF7L2 x WFS1 none 1111 10/10 0.546 0.010
Sex,BMI 812 10/10 0.535 0.090
HNF4A x KCNJ11 x TCF7L2 none 1122 10/10 0.565 0.001
Sex,BMI 836 10/10 0.546 0.040
HNF4A x KCNJ11 x WFS1 none 1105 10/10 0.541 0.031
Sex,B MI 802 10/10 0.549 0.034
HNF4A x TCF7L2 x WFS1 none 1096 10/10 0.551 0.011
Sex,BMI 798 10/10 0.540 0.072
KCNJ11 xTCF7L2 x WFS1 none 1080 10/10 0.528 0.122
Sex,BMI 799 10/10 0.497 0.549
HNF4A x KCNJ11 x TCF7L2 x WFS1 none 1068 10/10 0.512 0.313




SNP Epistasis & Ashkenazim T2D
PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9903
Author Contributions
Conceived and designed the experiments: RJN JW GA JW YY JC NB IB
BG MAP. Analyzed the data: RJN. Contributed reagents/materials/
analysis tools: JW. Wrote the paper: RJN. Revisions and final approval of
version to be published: J. Wasson J. Wainstein. Extensive revisions and
final approval of version to be published: GA. Extensive revisions and final
approval of version: BG. Revisions and final approval of version: YY JC
NB IB MAP.
References
1. Mensink M (2005) Lifestyle intervention, glucose tolerance, and risk of
developing type 2 diabetes mellitus. Metab Syndr Relat Disord 3: 26–34.
2. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009)
Potential etiologic and functional implications of genome-wide association loci
for human diseases and traits. Proc Natl Acad Sci U S A 106: 9362–9367.
3. Doria A, Patti ME, Kahn CR (2008) The emerging genetic architecture of type 2
diabetes. Cell Metab 8: 186–200.
4. Grant RW, Moore AF, Florez JC (2009) Genetic architecture of type 2 diabetes:
recent progress and clinical implications. Diabetes Care 32: 1107–1114.
5. Black MH, Fingerlin TE, Allayee H, Zhang W, Xiang AH, et al. (2008)
Evidence of interaction between PPARG2 and HNF4A contributing to variation
in insulin sensitivity in Mexican Americans. Diabetes 57: 1048–1056.
6. Cauchi S, Meyre D, Durand E, Proenca C, Marre M, et al. (2008) Post genome-
wide association studies of novel genes associated with type 2 diabetes show
gene-gene interaction and high predictive value. PLoS One 3: e2031.
7. Hansen SK, Nielsen EM, Ek J, Andersen G, Glumer C, et al. (2005) Analysis of
separate and combined effects of common variation in KCNJ11 and PPARG on
risk of type 2 diabetes. J Clin Endocrinol Metab 90: 3629–3637.
8. Miyake K, Yang W, Hara K, Yasuda K, Horikawa Y, et al. (2009) Construction
of a prediction model for type 2 diabetes mellitus in the Japanese population
based on 11 genes with strong evidence of the association. J Hum Genet 54:
236–241.
9. Qi L, van Dam RM, Asselbergs FW, Hu FB (2007) Gene-gene interactions
between HNF4A and KCNJ11 in predicting Type 2 diabetes in women. Diabet
Med 24: 1187–1191.
10. Sparso T, Grarup N, Andreasen C, Albrechtsen A, Holmkvist J, et al. (2009)
Combined analysis of 19 common validated type 2 diabetes susceptibility gene
variants shows moderate discriminative value and no evidence of gene-gene
interaction. Diabetologia 52: 1308–1314.
11. Winckler W, Weedon MN, Graham RR, McCarroll SA, Purcell S, et al. (2007)
Evaluation of common variants in the six known maturity-onset diabetes of the
young (MODY) genes for association with type 2 diabetes. Diabetes 56:
685–693.
12. Cho YM, Ritchie MD, Moore JH, Park JY, Lee KU, et al. (2004) Multifactor-
dimensionality reduction shows a two-locus interaction associated with Type 2
diabetes mellitus. Diabetologia 47: 549–554.
13. Weedon MN, McCarthy MI, Hitman G, Walker M, Groves CJ, et al. (2006)
Combining information from common type 2 diabetes risk polymorphisms
improves disease prediction. PLoS Med 3: e374.
14. Culverhouse R, Suarez BK, Lin J, Reich T (2002) A perspective on epistasis:
limits of models displaying no main effect. Am J Hum Genet 70: 461–471.
15. Hanlon P, Lorenz WA, Shao Z, Harper JM, Galecki AT, et al. (2006) Three-
locus and four-locus QTL interactions influence mouse insulin-like growth
factor-I. Physiol Genomics 26: 46–54.
16. Jarvis JP, Cheverud JM (2009) Epistasis and the evolutionary dynamics of
measured genotypic values during simulated serial bottlenecks. J Evol Biol 22:
1658–1668.
17. Barroso I, Luan J, Wheeler E, Whittaker P, Wasson J, et al. (2008) Population-
specific risk of type 2 diabetes conferred by HNF4A P2 promoter variants: a
lesson for replication studies. Diabetes 57: 3161–3165.
18. Alsmadi O, Al-Rubeaan K, Wakil SM, Imtiaz F, Mohamed G, et al. (2008)
Genetic study of Saudi diabetes (GSSD): significant association of the KCNJ11
E23K polymorphism with type 2 diabetes. Diabetes Metab Res Rev 24:
137–140.
19. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, et al. (2003) Large-
scale association studies of variants in genes encoding the pancreatic beta-cell
KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the
KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52: 568–572.
20. Love-Gregory L, Wasson J, Lin J, Skolnick G, Suarez B, et al. (2003) E23K
single nucleotide polymorphism in the islet ATP-sensitive potassium channel
gene (Kir6.2) contributes as much to the risk of Type II diabetes in Caucasians as
the PPARgamma Pro12Ala variant. Diabetologia 46: 136–137.
21. Schwanstecher C, Meyer U, Schwanstecher M (2002) K(IR)6.2 polymorphism
predisposes to type 2 diabetes by inducing overactivity of pancreatic beta-cell
ATP-sensitive K(+) channels. Diabetes 51: 875–879.
22. Florez JC, Jablonski KA, McAteer J, Sandhu MS, Wareham NJ, et al. (2008)
Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention
Program. Diabetologia 51: 451–457.
23. Franks PW, Rolandsson O, Debenham SL, Fawcett KA, Payne F, et al. (2008)
Replication of the association between variants in WFS1 and risk of type 2
diabetes in European populations. Diabetologia 51: 458–463.
24. Minton JA, Hattersley AT, Owen K, McCarthy MI, Walker M, et al. (2002)
Association studies of genetic variation in the WFS1 gene and type 2 diabetes in
U.K. populations. Diabetes 51: 1287–1290.
25. Sandhu MS, Weedon MN, Fawcett KA, Wasson J, Debenham SL, et al. (2007)
Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 39:
951–953.
26. Wasson J, Permutt MA (2008) Candidate gene studies reveal that the WFS1
gene joins the expanding list of novel type 2 diabetes genes. Diabetologia 51:
391–393.
27. Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, et al. (2006) A flexible
computational framework for detecting, characterizing, and interpreting
statistical patterns of epistasis in genetic studies of human disease susceptibility.
J Theor Biol 241: 252–261.
28. Permutt MA, Wasson JC, Suarez BK, Lin J, Thomas J, et al. (2001) A genome
scan for type 2 diabetes susceptibility loci in a genetically isolated population.
Diabetes 50: 681–685.
29. Jordes L (1992) Genetic Diseases in the Ashkenazi Population: Evolutionary
Considerations. In: Bonne´-Tamir B, Adam A, eds. Genetic Diversity Among
Jews: Diseases and Markers at the DNA Level. New York: Oxford University
Press. pp 305–318.
30. Atzmon G, Rincon M, Schechter CB, Shuldiner AR, Lipton RB, et al. (2006)
Lipoprotein genotype and conserved pathway for exceptional longevity in
humans. PLoS Biol 4: e113.
31. Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, et al. (2003)
Unique lipoprotein phenotype and genotype associated with exceptional
longevity. Jama 290: 2030–2040.
32. Wasson J, Skolnick G, Love-Gregory L, Permutt MA (2002) Assessing allele
frequencies of single nucleotide polymorphisms in DNA pools by pyrosequen-
cing technology. Biotechniques 32: 1144–1146, 1148, 1150 passim.
33. Atzmon G, Pollin TI, Crandall J, Tanner K, Schechter CB, et al. (2008)
Adiponectin levels and genotype: a potential regulator of life span in humans.
J Gerontol A Biol Sci Med Sci 63: 447–453.
34. Botto LD, Khoury MJ (2001) Commentary: facing the challenge of gene-
environment interaction: the two-by-four table and beyond. Am J Epidemiol
153: 1016–1020.
35. Hunter DJ (2005) Gene-environment interactions in human diseases. Nat Rev
Genet 6: 287–298.
36. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, et al. (2001)
Multifactor-dimensionality reduction reveals high-order interactions among
estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69:
138–147.
37. Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality reduction
software for detecting gene-gene and gene-environment interactions. Bioinfor-
matics 19: 376–382.
38. Velez DR, White BC, Motsinger AA, Bush WS, Ritchie MD, et al. (2007) A
balanced accuracy function for epistasis modeling in imbalanced datasets using
multifactor dimensionality reduction. Genet Epidemiol 31: 306–315.
39. Hastie T, Tibshiranai R, Friedman J (2001) The Elements of Statistical
Learning:Data Mining, Inference, and Prediction. New York: Springer-Verlag.
40. Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, et al. (2007) A generalized
combinatorial approach for detecting gene-by-gene and gene-by-environment
interactions with application to nicotine dependence. Am J Hum Genet 80:
1125–1137.
41. Weedon MN (2007) The importance of TCF7L2. Diabet Med 24: 1062–1066.
42. Hosmer DW, Lemeshow S (2000) Applied logistic regression New York: John
Wiley & Sons Inc.
43. Frayling TM, Wiltshire S, Hitman GA, Walker M, Levy JC, et al. (2003) Young-
onset type 2 diabetes families are the major contributors to genetic loci in the
Diabetes UK Warren 2 genome scan and identify putative novel loci on
chromosomes 8q21, 21q22, and 22q11. Diabetes 52: 1857–1863.
44. Franke L, van Bakel H, Fokkens L, de Jong ED, Egmont-Petersen M, et al.
(2006) Reconstruction of a functional human gene network, with an application
for prioritizing positional candidate genes. Am J Hum Genet 78: 1011–1025.
45. Riggs AC, Bernal-Mizrachi E, Ohsugi M, Wasson J, Fatrai S, et al. (2005) Mice
conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit
diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis.
Diabetologia 48: 2313–2321.
46. Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, et al. (2007) Macrosomia
and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations
in the HNF4A gene. PLoS Med 4: e118.
SNP Epistasis & Ashkenazim T2D
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9903
